Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.52 |
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68358 | 0.90 | HTR2A (0.45) | NPC1RAB9APKMMTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL68974 | 0.89 | HTR2A (0.44) | NPC1RAB9APKMMTNR1AMTNR1B | |
| SCHEMBL69150 | 0.85 | MEN1 (0.40) | KDM4ECYP3A4CYP2D6CYP2C9MEN1 | |
| SCHEMBL69527 | 0.84 | OPRM1 (0.51) | CYP2D6OPRM1OPRK1DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL69112 | 0.84 | MEN1 (0.40) | KDM4ECYP3A4CYP2D6CYP2C9BLM | |
| Hydrochloric Acid SCHEMBL70732 | 0.83 | OPRM1 (0.50) | CYP2D6OPRM1OPRK1DRD2DRD3 | |
| SCHEMBL68293 | 0.83 | ALOX5 (0.48) | MTNR1AMTNR1BOPRM1OPRK1DRD3 | |
| Hydrochloric Acid SCHEMBL69015 | 0.82 | HDAC1 (0.49) | BLMMEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL67162 | 0.82 | HTR2A (0.42) | NPC1RAB9APKMMTNR1AMTNR1B | |
| SCHEMBL69376 | 0.82 | MTNR1A (0.44) | NPC1RAB9APKMMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470877-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-06-25 | — | — | US | claimed |
| US-20120220592-A1 | 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-08-30 | — | — | US | claimed |
| US-7855227-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-12-21 | — | — | US | claimed |
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | NEWRON PHARMACEUTICALS S.P.A. | 2008-12-25 | — | — | US | claimed |
| US-8470877-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-06-25 | — | — | US | disclosed |
| US-8470877-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-06-25 | — | — | US | disclosed |
| US-8470877-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-06-25 | — | — | US | disclosed |
| US-20120220592-A1 | 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-08-30 | — | — | US | disclosed |
| US-20120220592-A1 | 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-08-30 | — | — | US | disclosed |
| US-20120220592-A1 | 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-08-30 | — | — | US | disclosed |
| US-8129427-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-03-06 | — | — | US | disclosed |
| US-8129427-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-03-06 | — | — | US | disclosed |
| US-7855227-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-12-21 | — | — | US | disclosed |
| US-7855227-B2 | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-12-21 | — | — | US | disclosed |
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | NEWRON PHARMACEUTICALS S.P.A. | 2008-12-25 | — | — | US | disclosed |
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | NEWRON PHARMACEUTICALS S.P.A. | 2008-12-25 | — | — | US | disclosed |
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | NEWRON PHARMACEUTICALS S.P.A. | 2008-12-25 | — | — | US | disclosed |
| EP-1963280-A1 | 2 -PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | Newron Pharmaceuticals S.p.A. (IT) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007071311-A1 | 2 -PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071311-A1 | 2 -PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319057-A1 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators | CACNA1A, CACNA1E, CACNA1I | NPC1 2394/4885RAB9A 1406/4885PKM 721/4885 |
| US-20120220592-A1 | 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | CACNA1A, CACNA1I, KCNN2 | NPC1 619/4885RAB9A 2501/4885PKM 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.